Neuralstem's ALS Stem Cell Treatment Featured on CNN
ROCKVILLE, Md., April 30 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that its stem cell treatment for ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease), currently in a FDA-approved Phase I clinical trial, was featured on CNN last night with Dr. Sanjay Gupta, in the piece entitled "Stem Cell Medical Breakthrough" http://www.cnn.com/video/#/video/health/2010/04/30/gupta.medical.breakthrough.cnn
The segment featured the first footage of the procedure, in which Neuralstem's spinal cord stem cells are injected directly into the gray matter of the patient's spinal cord.
"We applaud the courage and fortitude of all of the patients in our trial and their families, and we are particularly grateful to the patient featured in this segment for allowing the world to view his story," said Neuralstem CEO and President, Richard Garr.
For more patient information about the trial, please visit the Emory ALS Center website at http://tinyurl.com/yhxdxwb.
ROCKVILLE, Md., April 30 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that its stem cell treatment for ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease), currently in a FDA-approved Phase I clinical trial, was featured on CNN last night with Dr. Sanjay Gupta, in the piece entitled "Stem Cell Medical Breakthrough" http://www.cnn.com/video/#/video/health/2010/04/30/gupta.medical.breakthrough.cnn
The segment featured the first footage of the procedure, in which Neuralstem's spinal cord stem cells are injected directly into the gray matter of the patient's spinal cord.
"We applaud the courage and fortitude of all of the patients in our trial and their families, and we are particularly grateful to the patient featured in this segment for allowing the world to view his story," said Neuralstem CEO and President, Richard Garr.
For more patient information about the trial, please visit the Emory ALS Center website at http://tinyurl.com/yhxdxwb.